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TP53, TP63,a n dTP73 genes comprise the p53 family. Each gene produces protein isoforms through multiple mechanisms
including extensive alternative mRNA splicing. Accumulating evidence shows that these isoforms play a critical role in the
regulation of many biological processes in normal cells. Their abnormal expression contributes to tumorigenesis and has a
profound eﬀect on tumor response to curative therapy. This paper is an overview of isoform diversity in the p53 family and
its role in cancer.
1.Introduction
Alternative splicing allows a single gene to express multiple
protein variants. It is estimated that 92–95% of human mul-
tiexon genes undergo alternative splicing [1, 2]. Abnormal
alterations of splicing may interfere with normal cellular
homeostasis and lead to cancer development [3–5].
The p53 protein family is comprised of three tran-
scription factors: p53, p63, and p73. Phylogenetic analysis
revealed that this family originated from a p63/73-like ances-
tral gene early in metazoan evolution [6, 7]. Maintenance
of genetic stability of germ cells seems to be its ancestral
function [8]. The p53 family regulates many vital biological
processes, including cell diﬀerentiation, proliferation, and
cell death/apoptosis [9, 10]. Dysregulation of the p53 family
plays a critical role in tumorigenesis and signiﬁcantly aﬀects
tumor response to therapy. This review summarizes current
data on the regulation of p53, p63, and p73 isoforms and
their roles in cancer.
2. Structure and Function
p53, p63, and p73 genes are located on chromosomes
17p13.1, 3q27-29, and 1p36.2-3, respectively. These genes
encode proteins with similar domain structures and signif-
icant amino acid sequence homology in the transactivation,
DNA-binding and oligomerization domains (Figure 1). The
highest amino acid identity is in the DNA-binding domain
(∼60%). Evolutionally, this domain is the most conserved,
suggestingthatregulationoftranscriptionplaysapivotalrole
in an array of functions attributed to the p53 family. Less
similarityisfoundintheoligomerizationandtransactivation
domains (∼30%).
The founding member of the p53 family, the p53 protein,
had been discovered more than three decades ago [12, 13].
For a long time, it had been assumed that p53 is expressed
as a single polypeptide. However, when it had been found
that the p63 and p73 genes encoded a large variety of diverse
transcripts, the p53 gene transcription was revisited. Now we
know that p53 forms multiple variants.
Transcriptions of p53, p63, and p73 genes are regulated
by similar mechanisms. It is controlled by two promoters:
P1 and P2, where P2 is an alternative intragenic promoter
(Figure 1). One study in silico provided evidence for the
existence of a third putative promoter in the ﬁrst intron
of human TP73 gene [14]. Therefore, it would not be
surprising if additional gene promoters will be found in the
future.Anextensivealternativesplicingaddsfurtherdiversity
to the promoters’ products. The produced transcripts and
proteins can be generally categorized into two main groups,
termed TA and ΔN[ 15, 16]. TA variants contain the N-
terminal transactivation domain while ΔN isoforms lack
the entire (or part of) domain. It was initially thought
that ΔN isoforms are only generated by the P2 promoter
whereas the P1 promoter regulates TA isoforms. Further
analysis of alternative mRNA splicing revealed that some2 Journal of Nucleic Acids
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Figure 1: Architectures of human TP53, TP73, and TP63 genes. (A) TP53, TP73, and TP63 genes encode the transactivation (TAD), DNA-
binding (DBD), and oligomerization (OD) domains. TP73 and TP63 encode additional SAM (Sterile Alpha Motif) domain. Percentage
homology of residues between p53, p63, and p73 is shown [11]. (B) TP53, TP63, and TP73 genes have two promoters (P1 and P2). The P1
promoters produce transactivation-competent full-length proteins (TA) while the P2 promoters produce TAD-deﬁcient proteins (ΔN) with
dominant-negative functions. p53 gene transcription is initiated from two distinct sites (P1 and P1 ).
transcriptionally deﬁcient isoforms are products of the P1
promoter. For example, the P1 promoter of the TP73 gene
regulates TAp73 isoforms and isoforms, which lack the
TA domain: ΔEx2p73, ΔEx2/3p73, and ΔN p73. The latter
isoforms are missing either exon 2 (ΔEx2p73) or both exon
2a n d3( ΔEx2/3p73) or contain an additional exon 3 
(ΔN p73) [17, 18]. Other ΔNp73 transcripts are products
of the P2 promoter. Similar to p73, the P1 promoter of
the p53 gene produces transcriptionally active isoforms [5].
The alternative splicing is responsible for transcriptionally
deﬁcient isoforms of Δ40p53, which missing the ﬁrst 40
amino acids at the N-terminus [5, 19, 20]. Additional p53
transcriptionally deﬁcient isoforms (Δ133p53 and Δ160p53)
are regulated by the P2 promoter located in intron 4 of the
p53 gene [5, 21].
Additional diversity of p53, p63, and p73 transcripts
is generated by alternative splicing at the 3  end of the
transcripts (Figure 1). These splice variants are traditionallyJournal of Nucleic Acids 3
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Figure 2:Interactionsofp53familyisoforms.N-terminallytruncatedisoformsofp53,p73,andp63playadominant-negativeroleinhibiting
transcriptional and other biological activities of TA isoforms.
named with letters of the Greek alphabet. Initially, three such
splice variants have been described for p63 and p53 (α, β,
γ), and nine for p73 (α, β, γ, δ, ε, θ, ζ, η,a n dη1) [22–25].
Later, additional p63 splice variants (δ, ε) and p53 (δ, ε, ζ,
ΔE6) were reported [26–28]. However, it should be noted
that a majority of p53, p63, and p73 studies focus on a few
isoforms, primarily α, β,a n dγ. Little is known about the
functions of other isoforms. The combination of alternative
splicing at the 5  and 3  ends, alternative initiation of
translation and alternative promoter usage can signiﬁcantly
increase protein diversity. For example, N-terminal variants
(p53, Δ40p53, Δ133p53, and Δ160p53) can be produced in
α, β,a n dγ “ﬂavors” [20, 21]. Theoretically, the p53 gene can
produce at least 20 isoforms, p63 at least 10, and p73 more
than 40, though not all have been experimentally conﬁrmed.
p53, TAp63, and TAp73 share signiﬁcant functional
resemblance. They can induce cell cycle arrest, apoptosis, or
cellular senescence. This similarity can be explained, at least
inpart,bytransactivationofthesametranscriptionaltargets.
Genome-wide analyses found an overlap of the transcription
proﬁles of p53, TAp73, and TAp63, though unique targets
were identiﬁed as well. Analyses using chromatin immuno-
precipitation, reporter, and gel-shift assays found that TAp73
and TAp63 interact with p53-responsive elements.
The transactivation and apoptotic potential of p53,
TAp73, and TAp63 vary greatly depending on the isoform.
TAp63γ and TAp73β are similar to that of p53α [29]. Other
isoforms are considered less active on the p53 target gene
promoters [9, 23, 30]. Some isoforms are characterized by a
variation in domain structure. TAp73α and TAp63α have an
additional domain at the COOH-terminus that is not found
in p53. This domain, termed SAM or Sterile Alpha Motif, is
responsible for protein-protein interactions and is found in a
diverse range of proteins that are involved in developmental
regulation. It is also implicated in transcriptional repression
[31]. Beta and gamma isoforms of p53 are missing most
of the oligomerization domain that results in decreased
transcriptional activity [5, 32, 33].
ΔN isoforms function as dominant-negative inhibitors
of TA counterparts (Figure 2). Promoter competition and
heterocomplex formation have been suggested to explain
this phenomenon [17, 34, 35]. In the promoter competition
mechanism, the suggestion is that ΔNc o m p e t e so ﬀ TA
isoforms from their target gene promoters, thus preventing
eﬃcient transcription. In the heterocomplex formation
mechanism, ΔN isoforms would inhibit TA by forming
hetero-oligomeric complexes.
ΔN isoforms of p53 and p73 are regulated by a negative
feedback loop mechanism. Analogous mechanism was not
described for p63 despite its signiﬁcant similarity to p73. In
a nutshell, TA isoforms are able to induce transcription of
ΔN isoforms by activating P2 promoters. The induced ΔN
isoforms, in turn, inhibit TA isoforms. A good example of
these interactions is an induction of Δ133p53 by p53 [5, 36–
38]. Similarly, TAp73 and p53 are important regulators of
transcriptions of ΔNp73 [39]. It appears that the balance
between ΔN and TA isoforms is ﬁnely tuned to regulate the
activities of TA isoforms. The net eﬀect of these interactions
in a given context appears to be dependent on the TA/ΔN
expression ratio. Deregulation of this mechanism may lead
to tumor development [40–42]. However, it has become
clear that the role of ΔNi s o f o r m si sm u l t i f a c e t e d .T h e
dominant negative concept cannot explain the complexity of
all the interactions attributed toΔN isoforms. Several studies
reported that ΔN isoforms can retain transcription activity
through additional transactivation domains.
3. Role of p53 Isoforms in Cancer
Although many aspects of p53 biology have been thoroughly
investigated, the role and regulation of p53 isoforms remain
not well understood.
Recent studies suggested that Δ133p53 isoform may
play an oncogenic role. Mice overexpressing the Δ122p53
isoform (murine homolog of human Δ133p53) show
reduced apoptosis, increased cell proliferation and develop
a wide-spectrum of aggressive tumors including lymphoma,
osteosarcoma, and other malignant and benign tumors [43].
Another phenotypic characteristic of these mice is elevated4 Journal of Nucleic Acids
cytokine levels in the blood and widespread inﬂammation in
many organs. Interestingly, transgenic expression of another
p53 isoform, Δ40p53, does not lead to tumor formation
in mice, but is associated with a short life span, cognitive
decline,andovertdiabetes,suggestingasigniﬁcantdiﬀerence
between these isoforms [44–46].
Several studies reported an elevated expression of
Δ133p53 in tumors (Table 1). In breast tumors, 24 of 30
cases showed an increased expression of Δ133p53, but low or
undetectable levels in normal breast tissue [5]. An increase
of Δ133p53α mRNA was also found in renal cell carcinoma
[47]. In colon tumors, progression from colon adenoma
to carcinoma is accompanied by an increase of Δ133p53
mRNA. This study suggested that Δ133p53 helps to escape
from the senescence barrier during colon tumor progression
[48]. Interestingly, the Δ133p53 expression level is associated
with the mutation status of p53; colon tumors expressing
wildtype p53 had higher levels of Δ133p53 than p53 mutant
tumors[48].InadditiontoΔ133p53,anincreasedexpression
of Δ40p53 was also reported in human melanoma cell
lines and primary melanoma isolates [33]. However, not
a l lt u m o r so v e r e x p r e s sΔ133p53. Analysis of squamous
carcinomaoftheheadandneckdidnotrevealanysigniﬁcant
changes in the Δ133p53 levels, suggesting that this isoform
may only play a tumor-promoting role in a subset of tissues
[49].
Alterationsofp53β andp53γ isoformswerealsoreported
in diﬀerent types of cancers (Table 1). An increased expres-
sion of p53β was found in renal cell carcinoma and in
most melanoma cell lines. In renal cell carcinoma, p53β
expression was associated with tumor progression [47].
p53β was also found to correlate with worse recurrence-
free survival in ovarian cancer patients with functionally
active p53 [28]. Decreased p53β and p53γ mRNA levels
were reported in breast cancer [5]. In breast tumors, p53β
is associated with the expression of estrogen receptor but not
with disease outcome [50]. Breast cancer patients expressing
both mutant p53 and p53γ have lower cancer recurrence
and favorable prognosis [51]. Currently, speciﬁc functions
of p53β and p53γ remain unclear. A signiﬁcant hurdle to
the studies of p53 isoforms in tumors is the lack of isoform-
speciﬁcantibodies.Thegenerationofnewantibodies,animal
models, and additional tumor studies may help to better
understand the role of p53 isoforms in tumorigenesis.
4. Role of p73 Isoforms in Cancer
T h er o l eo fp 7 3i nt u m o r i g e n e s i si ss t i l lam a t t e ro fd e b a t e .
In contrast to p53, p73 is rarely mutated and frequently
o v e r e x p r e s s e di nh u m a nt u m o r s[ 23, 52–56]. An initial study
of p73-deﬁcient mice found a number of developmental
defects and no spontaneous tumors [57]. Follow-up studies
have revealed spontaneous tumorigenesis, although the late
onset of tumors and smaller tumor sizes compared to
p53-deﬁcient animals were reported. The basis for these
conﬂicting results in cancer susceptibility remains obscure
but might be related to the animal genetic background and
housing conditions. Mice with isoform-speciﬁc knockouts of
p73 have also been generated; phenotypes of these animals
generally reﬂect previously reported diﬀerences between p73
isoforms. TAp73 null mice are tumor prone while ΔNp73
knockouts have increased sensitivity to DNA-damaging
agents and elevated p53-dependent apoptosis [58, 59].
Several studies have found that N-terminally truncated
isoforms of p73 play an oncogenic role and are linked to
cancer development (Table 1). Targeted transgenic overex-
pression of human ΔEx2/3p73 in the mouse liver resulted
in the development of hepatocellular carcinoma [60]. The
N-terminally truncated isoforms are upregulated in many
human cancers including liver, ovarian, breast, vulvar can-
cers,andmelanoma[23,61–68].OverexpressionofΔEx2p73
andΔEx2/3p73wasfoundtobeassociatedwithmetastasesin
melanoma [68].
ΔNp73, which is produced by the P2 promoter, has also
been found to behave as an oncogene. ΔNp73 facilitates
immortalization of primary mouse embryonic ﬁbroblasts
and cooperates with oncogenic Ras in their transforma-
tion. These transformed cells produce tumors following a
subcutaneous injection into nude mice [121, 122]. ΔNp73
also inhibits diﬀerentiation of myoblasts and protects them
against apoptosis [123]. Studies by others and us found
that ΔNp73 is upregulated in a number of tumors and is
associated with metastases, chemotherapeutic failure, and
poorer patient prognosis [62, 74, 96, 124–130].
An important question is what causes deregulation of
p73 isoforms in tumors? One of the mechanisms is tumor-
speciﬁc alternative mRNA splicing. It has been demonstrated
that the alternative splicing causes incorporation of a new
exon 3’ into TAp73 transcripts resulting in a translational
switch from TAp73 to Np73 isoform [18, 61]. An interest-
ing observation was also made in hepatocellular carcinoma
whe r eanabe rrantswit c hfr o mT A p73t oΔEx2p73 wasfound
tobemediatedbytheactivationEGFRbyamphiregulin.This
leads to activation of JNK1 kinase, suppression of splicing
factor Slu7, and alternative splicing of p73 transcripts [65].
Activated Ras has also been shown to decrease TAp73 levels
and increase ΔNp73 expression during cellular transforma-
tion [131]. Abnormal regulation of the P2 promoter has also
beenreported. Wefoundthattranscriptional repressorHIC1
(Hypermethylated In Cancer 1) can suppress expression of
ΔNp73 by inhibiting the P2 promoter in normal cells. Loss
of HIC1 in esophagus and gastric cancer cells leads to up-
regulation of ΔNp73 [96] .I nas u b s e to ft u m o r s ,a b n o r m a l
epigenetic changes cause deregulation of p73 isoforms [132–
134]. Hypomethylation of the P2 promoter was found in
more than half of non-small lung cancers [76].
An increased expression of TAp73 isoforms was also
found in tumors, although its role remains unclear (Table 1).
Several studies suggested that in speciﬁc circumstances
TAp73 might play a tumor-promoting role [30, 135]. Inter-
estingly, some tumors tend to increase a variety of p73 splice
isoforms (Figure 3). In the normal colon and breast, p73α
and p73β isoforms are predominant whereas other spliced
variants (γ, δ, φ,a n dε) are primarily detected in colon and
breast cancers [15, 23]. This phenomenon was also observed
in acute myeloid leukemia. Moreover, the p73ε isoform was
only expressed in leukemic cells and completely absent inJournal of Nucleic Acids 5
Table 1: Summary of alterations of the p53 family members in human cancers.
Protein Cancer type Number of cases Ref.
Breast cancer
p53 (i) p53β was detected in 36% breast tumors and associated with the
expression of estrogen receptor (ER).
127 breast tumors [50] (ii) p53γ was detected in 37% breast tumors and associated with
mutations in the p53 gene.
(iii) Patients with mutant p53 and p53γ isoform had a low cancer
recurrence and an overall survival as good as that of patients with wild
type p53.
(i) p53, p53β, and p53γ mRNA, but not transcripts for Δ133p53α,
Δ133p53β mRNA, and Δ133p53γ,w e r ed e t e c t e di nn o r m a lb r e a s t
tissues. 30 breast tumors and 8 normal
breast samples [5]
(ii) p53β mRNA was detected in 10/30 tumors; Δ133p53α mRNA was
detected in 24/30 tumors; p53γ, Δ133p53β,a n dΔ133p53γ were
undetected in tumors.
(iii) Some tumors can express mutant p53 but wild type Δ133p53.
p73 (i) ΔTAp73 and TAp73 mRNA were upregulated in tumors.
60 breast cancers [62]
(ii) Expression of ΔEx2p73 (P = .05) is associated with vascular
invasion; a trend was found between ΔNp73 and vascular invasion
(P = .06).
(iii) Increased expression of ΔEx2p73 and ΔEx2/3p73 were associated
with ER status (P = .06 and P = .07); overexpression of TAp73 was
associated with progesterone receptor expression (P = .06).
(i) Mutational analysis revealed ﬁve silent mutations in 29 hereditary
tumors; no p73 mutations were detected in 48 sporadic cancers.
29 hereditary and 48 sporadic
breast cancers [52]
(i) Thirteen percent of informative cases showed LOH of the p73 gene;
no correlation was found between the p73 LOH and clinical features.
87 primary breast cancer specimens [69] (ii) No changes of p73 transcript levels in breast cancers compared to
normal breast tissues.
(iii) PCR-SSCP analysis did not detect any missense or frameshift
mutations in the p73 gene.
(i) Elevated expression of p73 mRNA was found in 29/77 breast tumors;
no correlation of p73 expression with the p53 status.
77 invasive breast cancers [23]
(ii) New p73 isoforms were identiﬁed.
(iii) No coding mutations were found in all coding exons.
p63 (i) p63 protein was strongly expressed in 13/15 metaplastic carcinomas.
189 invasive breast carcinomas [70] (ii) All metaplastic carcinomas with spindle cells and/or squamous
diﬀerentiation were positive for p63. One tumor out of 174
nonmetaplastic invasive carcinomas expressed p63.
(i) p63 protein expression was correlated with EBNA-1
immunostaining, suggesting a potential involvement of p63 in
mammary tumorigenesis associated with Epstein-Barr virus infection. 85 breast carcinomas [71]
(i) Survival analysis revealed a better prognosis for ER-positive patients
with p63 mRNA expression; no other correlations were found.
2,158 ER positive breast cancers and
140 normal breast biopsies. [72]6 Journal of Nucleic Acids
Table 1: Continued.
Protein Cancer type Number of cases Ref.
Lung cancer
p73 (i) p73 mRNA expression was increased in 87% (52/60) tumors
compared to normal lung tissues; no correlation with the p53 status was
found. 60 lung cancers [73]
(ii) No p73 gene ampliﬁcation was detected.
(iii) p73 expression correlated with cancer histology and patient age.
(i) ΔNp73 expression was detected in the cytoplasm of tumor cells in
77/132 patients with lung cancer. No expression was found in the
surrounding normal stromal cells. The expression of ΔNp73 was 52.2%,
50.0%, and 70.2% in stage I, II, and III tumor patients, respectively.
132 lung cancers [74]
(ii) ΔNp73 expression was a signiﬁcant independent factor for
predicting poor prognosis.
(i) ΔNp73 protein had primarily nuclear expression in 35/40 cases.
41 NSCLCs [75]
(ii) TAp73 protein was found in the cytoplasm in 28/40 cases.
(iii) ΔNp73 expression signiﬁcantly correlated with p53 expression.
(iv) No methylation of the P1 promoter was found; P2 promoter was
methylated in 17/41 tumors and partially or totally unmethylated in
24/41 cases.
(i) Hypermethylation of the P1 promoter of the p73 gene was relatively
uncommon.
102 NSCLCs [76] (ii) Hypomethylation of the P2 promoter was frequently found in
squamous cell carcinomas.
(i) Expression of ΔEx2p73 and ΔEx2/3p73 was increased; expression of
ΔNp73 and ΔN’p73 was decreased.
46 NSCLCs [42] (ii) Expression of p73 isoforms correlated with clinicopathological
variables.
p63 (i) p63 protein expression was detected in 109/118 squamous cell
carcinomas, 15/95 adenocarcinomas, 2/2 adenosquamous carcinomas,
4/6 large cell carcinomas, 9/20 poorly diﬀerentiated neuroendocrine
tumors, and 1/37 typical and atypical carcinoids. 221 NSCLCs, 57 stage I–IV
neuroendocrine tumors
[77] (ii) p63 expression was progressively increased from preneoplastic and
preinvasive lesions to invasive squamous cell carcinomas.
(iii) p63 immunoreactivity was correlated with the KI-67 labeling index
and inversely correlated with the tumor grade in squamous cell
carcinomas.
(i) p63 genomic sequence was ampliﬁed in 88% of squamous
carcinomas, in 42% of large cell carcinomas, and in 11% of
adenocarcinomas of the lung. Genomic ampliﬁcation of p63 is an early
event in the development of squamous carcinoma.
217 NSCLCs [78]
(ii) ΔNp63α was found to be the predominant p63 isoform in normal
bronchus and squamous carcinomas but not in normal lung or in
adenocarcinomas.
(iii) p63 genomic ampliﬁcation and protein staining intensity were
associated with better survival.
(i) p63 protein immunopositivity was found in 80% (48/60) NLCLCs.
60 NSCLCs [79]
(ii) Expression of p63 protein was associated with lymph node
metastasis and histological classiﬁcation.
(iii) Expressions of p63 and p73 proteins were positively correlated.Journal of Nucleic Acids 7
Table 1: Continued.
Protein Cancer type Number of cases Ref.
(i) Nuclear ΔNp63 staining was found in 77/161 specimens.
161 squamous cell carcinomas [80] (ii) No signiﬁcant correlation was observed between ΔNp63 expression
and clinicopathological variables.
(i) Most of the p63 expression detected in nonneoplastic lung tissue was
localized to the nuclei of the bronchiolar basal cells. Nucleic and
cytoplasmic expression of p63 protein was found in 46/92 (50%) and
47/92 (51%) cases. Nuclear localization of p63 was correlated with
nuclear accumulation of p53, but was not associated with patient
survival.
92 lung adenocarcinomas [81]
(ii) Cytoplasmic expression of p63 was found to be an adverse
prognostic factor in patients with lung adenocarcinoma.
(i) ΔNp63 isoform was upregulated (P = .02), and TAp63 was slightly
downregulated (P = .01). 46 NSCLCs [42]
(ii) TAp63 expression correlated with patient survival in non-squamous
tumors.
Prostate cancer
p73 (i) No tumor-speciﬁc mutations were found in the p73 gene.
27 prostate cancers and 4 prostate
cell lines [82] (ii) p73 was biallelically expressed in both normal prostate and tumor
tissues.
(iii) p73 mRNA expression was not altered in tumors compared to
normal prostate.
(i) Signiﬁcant increase of ΔNp73 mRNA was found in 20/33 (60%)
prostate carcinomas and 17/24 (70%) benign prostate hyperplasias.
ΔNp73 mRNA was not detected in the normal prostate. None of the
specimen expressed ΔN p73.
33 prostate carcinomas, 24 benign
prostatic hyperplasia samples, and
5 normal samples
[83]
(ii) ΔNp73 expression was signiﬁcantly associated with the Gleason
score. No correlation was found between TAp73 expression and clinical
variables.
p63 (i) p63 expression was reduced in prostate carcinomas compared to
matched normal tissues.
20 tumors, 20 metastases, 28
xenografts, and 7 prostate cancer
cell lines
[84]
(ii) One tumor patient had a somatic mutation in exon 11, one prostate
cell line, CWR22Rv1, expressed mutant p63 (G to T substitution in exon
8).
(i) Increased expression of cytoplasmic p63 proteins was associated with
increased cancer mortality. Cytoplasmic expression was also associated
with reduced levels of apoptosis and increased cellular proliferation.
298 prostate cancers [85]
Colon cancer
p53 (i) Colon adenomas with senescence phenotype expressed elevated
levels of p53β and reduced levels of Δ133p53. Colon carcinoma tissues
were characterized by increased Δ133p53 expression. Colon carcinomas
(stage I and II) had increased levels of p53β mRNA.
29 colon carcinomas, 8 adenomas,
and 9 normal colon specimens [48]
p73 (i) p73 protein levels were signiﬁcantly higher in primary colorectal
carcinomas.
56 colon carcinomas with matched
normal specimens
[86]
(ii) p73 and VEGF expression levels were correlated (P = .016); p73
positive colorectal adenocarcinoma showed signiﬁcantly greater
vascularity.
(iii) There were no associations between p73 immunostaining and
tumor stage or diﬀerentiation.8 Journal of Nucleic Acids
Table 1: Continued.
Protein Cancer type Number of cases Ref.
(i) TAp73 and ΔTAp73 were signiﬁcantly co-upregulated in colon
cancers.
113 colon cancers [62]
(ii) Expression of ΔEx2/3p73 and ΔNp73 isoforms was associated with
tumor stage (P = .03; P = .011).
(iii) ΔNp73 overexpression was signiﬁcantly associated with vascular
invasion (P = .02).
(iv) High levels of ΔEx2/3p73 were associated with lymph node
metastases (P = .04).
(v) Up-regulation of TAp73 was associated with tumor localization
(P = .004).
(vi) Negative p53 staining correlated with overexpression of ΔEx2p73
and TAp73 (P = .05; P = .05).
p63 (i) p63 protein was primarily expressed in villous adenomas and poorly
diﬀerentiated adenocarcinomas. 30 colon adenomas,
30 adenocarcinomas
[87]
(ii) p63 expression was not associated with p53.
Bladder cancer
p73 (i) p73 mRNA was increased in 18/45 bladder carcinomas and showed
a strong correlation with tumor stage or grade; no allelic loss was found.
High p73 expression was observed in 4/18 (22.2%), 5/14 (35.7%), and
9/13 (69.2%) of grade I, II, and III tumors, respectively. 45 primary bladder carcinomas [88]
(ii) No p73 gene mutations were found by SSCP analysis.
(iii) No relationship between p73 and p53 mutations, expression of p21
and MDM2 was found.
(i) p73 mRNA was increased in 22/23 bladder cancers.
23 primary invasive bladder cancers
with matched normal tissues,
7 bladder cancer cell lines
[55]
(ii) No tumor-speciﬁc mutations were found in coding exons of
the p73 gene.
(iii) p73 was biallelically expressed in the normal bladder and cancer
tissues.
(i) p73 protein was undetectable or low in 104/154 (68%) transitional
cell carcinomas of the bladder, primarily in invasive tumors. 154 bladder transitional cell
carcinomas
[89]
(ii) Expression of p73 was associated with bladder cancer progression.
p63 (i) TAp63 was reduced in 25/47 (53.2%) bladder carcinomas. The
downregulation of TAp63 was associated with tumor stage and grade.
47 bladder carcinomas and
12 normal specimens [90]
(ii) ΔNp63 was increased in 30/47 (63.8%) tumors.
(iii) No mutations of p63 gene were found.
(iv) No association between p63 expression and the mutational status of
p53 or expression of p21Waf1, MDM2, and 14-3-3σ in carcinomas was
found.
(i) p63 immunostaining was decreased along tumor progression. Basal
and intermediate cell layers of normal urothelium showed intense
nuclear p63 staining. Lower p63 expression was signiﬁcantly associated
with TNM stage, lymph-node metastasis, and poor prognosis.
75 tumors [91]
(i) ΔNp63 protein expression was increased in tumors and undetectable
in normal bladder urothelium. ΔNp63 expression was associated with
an aggressive clinical course and poor prognosis. Patients with
ΔNp63-negative tumors had a higher recurrence rate than those with
ΔNp63-positive tumors.
202 bladder carcinomas and 10
normal specimens [92]
(ii) p63α expression was decreased in bladder carcinomas.Journal of Nucleic Acids 9
Table 1: Continued.
Protein Cancer type Number of cases Ref.
Melanoma
p53 (i) p53β and Δ40p53 mRNAs were expressed in the majority of
melanoma cell lines. These isoforms were absent or expressed at low
levels in ﬁbroblasts and melanocytes. Δ40p53 was found to inhibit
p53-dependent transcription whereas p53β enhances it.
19 melanoma cell lines [33]
p73 (i) p73 mRNA expressed in the majority of human melanoma cell lines,
melanocytic nevi, primary malignant melanomas, and metastases.
9 cell lines, 17 melanocytic nevi,
17 primary melanomas, and 20
metastases
[93]
(ii) No mutation was found in the DNA-binding domain of p73 in 9
melanoma cell lines and 5 metastatic tumors.
(i) ΔEx2p73 and ΔEx2/3p73 mRNAs were signiﬁcantly upregulated in
melanoma metastases. 8 benign melanocytic nevi,
8 primary melanomas, and
19 melanoma metastases
[68] (ii) ΔNp73 was the predominant isoform in benign nevi.
(iii) An increased expression of ΔEx2p73 and ΔEx2/3p73 isoforms
correlated with high levels of TAp73 and E2F1.
Gastric cancer
p73 (i) p73 expression was increased in 37/39 gastric carcinomas and 14/16
matched sets.
39 gastric carcinomas [94] (ii) No allelic deletions or mutations in the p73 gene were detected.
(iii) There was no association between p73 expression and mutational
status of p53 or expression of p21/Waf1.
(i) p73 expression was found in 33/68 tumors from 24 patients with
multiple simultaneous gastric cancers. 68 gastric carcinomas from 32
patients
[95]
(ii) No mutation in the DNA-binding domain of p73 was found.
(iii) No correlations were found between p73 expression and clinical
variables.
(i) ΔNp73 mRNA and protein were increased in gastric tumors.
185 tumors [96] (ii) Up-regulation of ΔNp73 protein was signiﬁcantly associated with
poor patient survival. The median survival time for patients with
increased ΔNp73 was 20 months whereas that of patients with a
negative/weak expression was 47 months.
p63 (i) p63 expression was found in 25/68 tumors from 24 patients with
multiple simultaneous gastric cancer. p63 expression was signiﬁcantly
higher in high-grade diﬀuse tumors. An increased expression of p63 was
observed in intestinal metaplasia and atrophic gastritis. Nonneoplastic
tissues had low levels of p63.
68 gastric carcinomas from
32 patients
[95]
(ii) Expression of TAp63 and ΔNp63 was not associated with the
mutational status of p53, tumor stage, or prognosis.
Esophageal Cancer
p73 (i) Low expression of p73 mRNA in 8 analyzed tumors.
48 esophageal tumors (47 ESCCs
and 1 EA) [56] (ii) No tumor-speciﬁc mutation was found.
(iii) LOH for p73 was found in 2/25 (8%) tumors.
(i) LOH was found in 9/14 cases.
15 ESCCs [97]
(ii) No mutations in the p73 gene were detected in tumor samples. A
polymorphism at codon 173 of p73 was identiﬁed.
(iii) p73 mRNA was overexpressed in 9/15 tumor samples. Four cases
showed loss of imprinting. Expression of p73 correlated with p53
mutations.10 Journal of Nucleic Acids
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(i) p73 immunoreactivity was reduced with cancer invasion.
106 esophageal cancers [98]
(ii) No associations were found between p73 expression and
clinicopathological variables.
(iii) Inverse correlation between p73 expression and p53 status was
found. Expression of p21 correlated with the p73 expression.
(i) Expression of ΔNp73 mRNA and protein was increased in esophageal
adenocarcinoma.
68 EA and GEJ tumors [96]
(ii) HIC (hypermethylated in tumors 1) protein, but not p53, was found
to regulate ΔNp73.
(iii) Expression of ΔNp73 signiﬁcantly correlated with the expression of
TAp73.
p63 (i) p63 protein was diﬀusely expressed in all cases of esophageal
squamous cell dysplasia and carcinoma.
20 normal esophageal squamous
tissues, 4 squamous dysplasias,
7 squamous cell carcinomas, 10 BE,
13 BE-associated multilayered
epithelial specimens, 10 esophageal
mucosal gland duct specimens,
12 BE-associated dysplasias, and
7 BE-associated adenocarcinomas
[99]
(ii) No expression was found in all cases of esophageal adenocarcinoma
and Barrett’s esophagus.
(iii) ΔNp63 mRNA was a predominant isoform in all benign and
neoplastic squamous tissues.
(i) p63 expression was restricted to the basal cell layer in normal
esophageal epithelium. Strong expression of p63 was frequent ﬁnding in
squamous precancerous and cancerous lesions. BE-derived lesions
expressed p63 at low levels.
50 esophageal adenocarcinomas, 41
adjacent specialized metaplastic
epithelium, 27 low-grade
intraepithelial neoplasias, and 21
high-grade intraepithelial
neoplasias, 50 ESCCs, 4 squamous
low-grade intraepithelial neoplasias,
and 18 squamous high-grade
intraepithelial neoplasias
[100]
(ii) p63 gene ampliﬁcation was found to be infrequent in esophageal
malignancies. p63 gene ampliﬁcation was found in 2/10 squamous cell
carcinomas and in 1/10 adenocarcinomas.
(i) ΔNp63 protein was expressed in 32% and 64% carcinomas with and
without adventitial invasion, and in 37% and 65% with and without
lymph node metastasis, respectively. A better prognosis was observed in
patients with ΔNp63 expression.
61 ESCCs [101]
(ii) ΔNp63 expression was associated with patient survival. Decreased
expression of p63 was more frequent in advanced carcinomas.
(i) p63 expressed in 171/180 (95%) patients.
180 ESCCs [102]
(ii) Patients with p63-positive tumors had better overall survival
compared to patients with p63-negative tumors.
(iii) Correlation between p63 and clinicopathological parameters was
not signiﬁcant. Negative p63 expression tended to correlate with distant
metastases and clinical stage.
(i) Expression of p63 protein was increased in tumors. It was detected in
21/40 (52.5%) ESCCs. 40 ESCCs and 40 normal
esophageal specimens [103] (ii) No associations were observed between expression of p63 protein
and clinicopathological variables.
Head and neck cancer
p53 (i) p53β mRNA was detected in 18/20 tumor specimens (T), 13/14
normal tissues adjacent to the tumor (N), and 6/6 normal control
specimens (NS); p53γ was detected in 5/20 (T), 3/14 (N), and 6/6 (NS);
133p53α expressed in 7/20 (T), 9/14 (N), and 3/14 (NS); Δ133p53β
was detected in 3/20 (T), 2/14 (N); Δ133p53γ expressed in 4/20 (T),
1/14 (N), 2/6 (NS).
21 squamous cell carcinomas,
16 normal specimens adjacent to
tumors, 8 normal specimens
[49]Journal of Nucleic Acids 11
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p73 (i) Two missense mutations at codons 469 and 477 and one silent
mutation at codon 349 in the p73 gene were found. 67 primary oral and laryngeal
squamous cell carcinomas [104] (ii) Increased p73 expression was found in 5/21 (23.8%) patients;
decreased expression was observed in 6/21(28.5%) patients.
(i) p73 mRNA was decreased in 5/17 (30%) tumors. No mutation and
LOH was found in the p73 gene. 50 squamous cell carcinomas [105]
(ii) No correlation was found between p73 and p53 protein expression.
(i) p73 protein expression was detected in 12/68 (18%) normal mucosas
and 32/68 (47%) HNSCC.
68 squamous cell carcinomas [106] (ii) No p73 mutations were found in primary and recurrent carcinomas.
(iii) No correlation was found between protein expression of p73 and
p53.
(i) p73 was signiﬁcantly elevated in buccal epithelial dysplasia (protein)
and squamous cell carcinomas (protein and mRNA) compared to
normal control tissues.
25 buccal squamous cell
carcinomas, 75 epithelial dysplasias [107]
(ii) p73 expression was associated with cervical lymph node metastasis
for cases of buccal SCC.
p63 (i) Positive immunostaining for p63 was detected in 55/68 (81%)
carcinomas, 40/68 (59%) normal tissues.
68 squamous cell carcinomas [106] (ii) No p63 mutations were detected in primary and recurrent
carcinomas.
(iii) No correlation was found between p63 and p53 protein expression.
(i) Expression of p63 was associated with tumor diﬀerentiation.
p63 expression was increased in poorly diﬀerentiated tumors.
96 oral squamous cell carcinomas
and 10 normal specimens [108] (ii) Increased p63 expression was associated with poor patient survival.
No signiﬁcant correlations were found between p63 expression and sex,
age, tumor size, staging, recurrence, and metastasis. Tumors with diﬀuse
p63 expression were more aggressive and poorly diﬀerentiated.
Cervical cancer
p73 (i) ΔNp73 and TAp73α proteins were overexpressed in tumors. 117 cervical squamous cell
carcinomas and 113 normal
specimens
[109] (ii) The overexpression of ΔNp73 was correlated with the resistance to
radiation therapy. An increased expression of TAp73α was detected in
the majority of cervical squamous cell carcinomas sensitive to
irradiation.
(iii) ΔNp73 expression was associated with recurrence of the disease and
an adverse outcome. TAp73α predicted a better survival.
(i) Higher TAp73 expression was found in high-grade lesions and
carcinomas (P<. 0001).
91 high-grade and 107 low-grade
squamous intraepithelial lesions, 212
ASC-US, 56 squamous cell
carcinomas, and 63 normal specimens
[110]
(ii) No correlation was found between p73 and p63 immunostainings.
p63 (i) Expression of p63 protein was high in 97% squamous cell
carcinomas. p63 is a strong marker for squamous diﬀerentiation.
250 cervical carcinomas [111] (ii) Transitions from squamous to columnar or undiﬀerentiated tumors
coincided with the loss of p63 expression.
(iii) HPV16 positivity and p63 expression were strong associated.
(i) ΔNp63 staining was increased with tumor progression. All SCCs,
transitional cell carcinomas, and adenoid basal carcinomas were positive
for p63.
127 uterine cervical tissues with
various lesions [112]
(ii) ΔNp63 protein was undetected in all adenocarcinomas.12 Journal of Nucleic Acids
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(i) Increased p63 immunostaining was found in high-grade lesions and
cervical carcinomas.
91 high-grade and 107 low-grade
squamous intraepithelial lesions,
212 ASC-US, 56 squamous cell
carcinomas, and 63 normal
specimens
[110] (ii) Signiﬁcant correlation was found between the presence of high-risk
HPV and p63 expression.
(iii) No correlation was found between p63 and p73 immunostainings.
Renal cancer
p53 (i) All six p53 isoforms were detected in tumor and normal tissues with
the exception of Δ133p53β, which was not detected in normal tissues. 41 renal cell carcinomas and normal
tissues adjacent to tumor [47] (ii) p53β mRNA was signiﬁcantly upregulated in tumor samples
(P<. 001) and associated with tumor stage.
p73 (i) Monoallelic expression of p73 was found in 11/12 normal tissues;
biallelic expression in 8/12 cancers. 28 renal cell carcinomas [113]
p63 (i) p63 expression was detected in 25/27 (92.6%) urothelial carcinomas.
None of the studied renal cell carcinomas was positive for p63. p63
expression correlated with tumor stage, grade and survival time, but not
with the tumor progression.
42 renal cell carcinomas and 27
renal pelvis urothelial carcinomas [114]
Thyroid cancer
p73 (i) p73 transcripts were downregulated in adenomas and diﬀerentiated
carcinomas.
102 thyroid tissues from 60 patients [115] (ii) Expression of TAp73 and ΔNp73 transcripts correlated with
expression of p53, p14ARF, and p16INK4a mRNA in normal tissue.
These correlations were lost in carcinomas.
(i) ΔNp73 was expressed in 27.3% follicular adenomas, 85.4% follicular
carcinomas, 99.2% papillary carcinomas, and 95.7% anaplastic
carcinomas. Normal follicular cells were negative for ΔNp73 protein. In
papillary carcinoma, ΔNp73 levels were inversely correlated with tumor
size, extrathyroid extensions, and metastases. In anaplastic carcinoma,
ΔNp73 expression was signiﬁcantly lower than in papillary carcinoma.
223 thyroid neoplasms [116]
p63 (i) TAp63α protein was expressed in 25/27 thyroid cancers 1/7 benign
adenomas, but not in normal thyroid (0/8). TAp63α transcripts, but not
TAp63β,T A p 6 3 γ,a n dΔNp63, were expressed in tumors. Thyroid cancer
cell lines also expressed p63.
2 7t h y r o i dc a n c e r s ,1 1c e l ll i n e s [ 117]
Pancreatic cancer
p73 (i) Expression of p73 protein was detected in 45.6% cancers and was
primarily found in cystic adenocarcinomas.
[118] (ii) p73 expression was inversely correlated with lymph node metastasis,
tumor size, and Ki-67 labeling index.
(iii) No correlation was found between p73 and p53 protein expression.
(i) p73 methylation was found in more than 50% noninvasive and
invasive tumors.
28 intraductal papillary mucinous
neoplasms [119]
p63 (i) Overexpression of p63 protein was observed in 68.2% cancers.
(ii) p63 expression was not associated with clinicopathological variables. [118]
(iii) No correlation was found between p63 and p53 protein expression.
(i) No ΔNp63 protein expression was found in normal pancreatic ducts
and all pancreatic intraepithelial neoplasias. Among invasive
carcinomas, ΔNp63 expression was detected only in areas of squamous
diﬀerentiation and was completely absent in ordinary ductal areas.
ΔNp63 is a reliable marker of squamous diﬀerentiation in the pancreas.
It was valuable in distinguishing squamous/transitional metaplasia from
PanINs.
25 nonneoplastic pancreata, 25
pancreatic intraepithelial neoplasia,
and 50 pancreatic ductal
adenocarcinomas
[120]Journal of Nucleic Acids 13
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Figure 3: An increased diversity of alternatively spliced species of p73 in colon adenocarcinoma. p73 gene transcription was analyzed in 10
colon tumors and normal colonic mucosa by RT-PCR. Normal specimen 2 represents 14 pooled normal samples. For details, see Vilgelm et
al. [15].
mature myeloid cells [136]. It is currently unclear what role
these changes play in tumorigenesis.
5. Role of p63 Isoforms in Cancer
Similar to p73, mutations in the p63 gene are rare in human
cancers [90, 137, 138]. Several studies reported that ΔNp63
has oncogenic properties. Ectopic overexpression of ΔNp63
inRat-1Acellspromotescolonyformationinsoftagar.When
xenografted into immunocompromised mice, these cells
formed tumors [139]. ΔNp63α inhibits oncogene-induced
cellular senescence and cooperates with Ras to promote
tumor-initiating stem-like proliferation [140]. Analysis of
p63-deﬁcientmiceledtoconﬂictingresultswithregardtothe
p63 role in tumorigenesis. p63−/− null mice showed striking
developmental defects demonstrating a critical role of p63 in
epithelial development [141, 142]. p63+/− heterozygous mice
were shown to be susceptible to tumor development [143].
However, other mouse models were not consistent with this
observation. Conﬂicting phenotypes of TAp63 and ΔNp63
transgenic mice have also been reported [144, 145].
ΔNp63 is a predominant isoform expressed in most
epithelial cells. Overexpression of ΔNp63 is found in cancers
of nasopharyngeal, head and neck, urinary tract, lung, and
ovarian tumors and correlated with poor outcome [78, 146–
149]. In metastases, ΔNp63 expression was found to be
reduced or lost [91, 101]. Microarray analyses revealed the
up-regulation of genes associated with tumor invasion and
metastasis in p63-deﬁcient cells [150]. It was also reported
that p63 suppresses the TGFβ-dependent cell migration,
invasion, and metastasis [151]. This suggests that ΔNp63
plays a dual role by promoting tumor development but
suppressing metastases [151, 152]. Expression of ΔNp63 was
found to be associated with an increased chemoresistance in
as u b s e to fb r e a s ta n dh e a da n dn e c kt u m o r s[ 153, 154].
TAp63 isoforms induce cellular senescence and inhibit
cell proliferation [155–157]. TAp63 deﬁciency increases
proliferation and enhances Ras-mediated oncogenesis [155].
Decreased TAp63 expression is associated with metastasis
in bladder and breast cancers as well as poor outcome
[42, 90, 158]. TAp63 impedes the metastatic potential of
epithelial tumors by controlling the expression of a crucial
set of metastasis suppressor genes [151, 159].
Clearly, additional studies are needed to understand the
complex regulation of p63 isoforms.
6. Interplayof p53/p63/p73 Isoforms in
Human Cancers
Interactions between members of the p53 family and their
isoforms have a profound eﬀect on tumorigenesis and
anticancer drug response. Perhaps, the most studied are
interactions between ΔN and TA isoforms. Inhibition of
TAp73 by ΔNp63 has been shown to negatively aﬀect the
response to platinum-based chemotherapy in head and
neck squamous cell carcinomas and a subset of breast
tumors [153, 154]. In carcinomas of ovary and child-
hood acute lymphoblastic leukemia, increased expression
of dominant-negative p73 isoforms correlates with resis-
tance to conventional chemotherapy [129, 130]. Moreover,
ΔNp73 is primarily expressed in ovarian tumors, which
express wildtype p53 [64]. However, crosstalk between the
p53 family members is not limited to dominant-negative
interactions. Accumulating evidence suggests that the p53
family interacts on multiple levels comprising protein-
protein interactions between multiple p53, p63, and p73
isoforms, shared regulation of target genes as well as TP53
and TP73 gene promoters [160–163]. In addition, mutant
p53 can aﬀect activities of TAp73 and TAp63. It has been
shown that certain tumor-derived p53 mutants (R175H,
R248W, Y220C, R249S, R283H, and D281G) can physically
associate and inhibit activation of TAp73 and/or TAp63
[164–166].
Current analyses suggest that the function of a particular
isoform needs to be investigated in the context of expression
of other isoforms. For example, ΔNp73β inhibits p53-
dependent apoptosis in primary sympathetic neurons [167],
but when overexpressed in cancer cells, ΔNp73β induces cell
cycle arrest and apoptosis [168].
An interesting observation has been made in mouse
embryonic ﬁbroblasts, where the combined loss of p73 and
p63 results in the failure of p53 to induce apoptosis in
response to DNA damage [169]. More recent studies have
reported that the p53 family members can simultaneously
co-occupy the promoters of p53 target genes and regulate
their transcription [15, 170, 171]. Notably, the integral
activity of the entire p53 family, as measured by reporter14 Journal of Nucleic Acids
analysis, is a better predictor of chemotherapeutic drug
response than p53 status alone [15].
7. Conclusion
The p53 family plays a pivotal role in the control of many
criticalcellularfunctions.Inrecentyears,ithasbeenrevealed
that all members of the p53 family are expressed as a
diverse variety of isoforms. We only just started to uncover
the mechanisms that regulate this diversity. A number of
studies also provided the ﬁrst glimpses of their functional
signiﬁcance. Clearly, isoforms add a new level of functional
regulation to many critical biological processes including cell
death, proliferation, cell cycle control, and tumorigenesis.
Depending on the isoform expressed, the role of a gene
can dramatically change from a tumor suppressor to an
oncogene. It is also clear that p53, p73, and p63 isoforms
tightly interact. A better understanding of this interacting
networkanditsregulationholdsthekeytofuturetherapeutic
beneﬁts.
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